Análisis costo versus efectividad del Etanercept, Infliximab y Adalimumab, en pacientes con artritis reumatoide refractaria

Abstract

Currently there are several technologies to treat rheumatoid arthritis (RA), which has become an industry since the treatments for it can be for long periods of time, with significant costs for the Colombian health system. Health institutions face a major challenge in trying to improve the quality of life of patients through new therapeutic alternatives using immunomodulatory drugs such as tumor necrosis factor antagonists (anti-TNF), however, the economic efficiency of this type of technology is still an aspect that health institutions are seeking to optimize.